• Rucaparib (AG-014699): Catalyzing Next-Gen DNA Damage Resear

  2026-06-29

  This thought-leadership article delivers mechanistic insights and strategic guidance for translational researchers using Rucaparib (AG-014699) as a potent PARP1 inhibitor. Bridging recent discoveries in DNA repair, radiosensitization, and regulated cell death, it details how APExBIO’s Rucaparib product enables robust, reproducible experimentation and positions researchers at the forefront of precision oncology.

• Ultra-Sensitive Yeast Platform for mTOR Inhibitor Discovery

  2026-06-28

  The referenced study presents a highly sensitive yeast-based system capable of detecting TOR/mTOR inhibitors with unprecedented precision, enabling rapid and cost-effective screening. This work not only accelerates the identification of geroprotective and anti-cancer agents but also clarifies the pathway specificity of candidate molecules such as Nebivolol hydrochloride.

• PARP Inhibition Beyond BRCA: Translational Insights with MK-

  2026-06-27

  This thought-leadership article explores how the mechanistic landscape of PARP inhibition—long dominated by BRCA-deficient cancer paradigms—is being reshaped by emerging discoveries in spliceosome regulation and combination therapeutics. By fusing evidence from hepatocellular carcinoma (HCC) models, advanced protocol strategies, and the unique properties of MK-4827 (Niraparib), the article offers actionable guidance for translational researchers aiming to broaden the impact of DNA damage repair inhibition. Strategic recommendations are interwoven with mechanistic insights, positioning APExBIO’s MK-4827 as an essential tool in the evolving field of cancer research.

• Tamsulosin: Applied Workflows and Troubleshooting in Urologi

  2026-06-26

  Tamsulosin ((R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide) enables precise, reproducible modeling of smooth muscle relaxation and urinary flow restoration in bench-to-bedside workflows. See how leading labs optimize solubility, dosing, and protocol integration, while leveraging the latest biomarker insights from prostate cancer research.

• BMAL1 Modulates Endothelial Apoptosis via STAT6 Repression

  2026-06-26

  This study elucidates how the transcription factor BMAL1 inhibits endothelial cell apoptosis by repressing STAT6 expression, using both in vivo and in vitro models of corneal neovascularization. These findings refine our understanding of vascular regulation and suggest BMAL1-STAT6 as a potential therapeutic axis in treating pathological angiogenesis.

• ERAD-Hijacking Chimeras Enable Targeted Degradation of TM Pr

  2026-06-25

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a new class of small molecules that harness the ER-associated degradation pathway to achieve highly selective degradation of transmembrane proteins. This strategy demonstrates sub-nanomolar efficacy against PD-L1 and reveals new opportunities for drug discovery and mechanistic research targeting previously intractable membrane proteins.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-06-25

  Wang et al. (2018) provide the first direct evidence that type III grass carp reovirus (GCRV104) enters CIK cells via clathrin-mediated, pH-dependent endocytosis, distinguishing this route from other viral entry mechanisms. Their systematic pharmacological inhibitor analysis clarifies the contributions of dynamin and endosomal acidification, while excluding pathways involving Pak1 inhibition.

• Thiothixene Stimulates Macrophage Efferocytosis via Arginase

  2026-06-24

  The reference study demonstrates that thiothixene, a typical antipsychotic agent, significantly enhances macrophage efferocytosis by upregulating Arginase 1 through the Stra6l-mediated vitamin A signaling pathway. This finding bridges neuropsychiatric pharmacology and immunomodulation, revealing potential therapeutic avenues for diseases marked by defective cell clearance.

• Crizotinib Hydrochloride: ALK Kinase Inhibitor in Tumor Asse

  2026-06-23

  Crizotinib hydrochloride empowers researchers to dissect ALK and ROS1-driven oncogenic pathways within advanced gastric cancer assembloid platforms, accurately modeling the tumor microenvironment and drug resistance mechanisms. This workflow-centric guide delivers actionable protocol enhancements, troubleshooting tips, and expert insights to optimize kinase inhibitor studies using APExBIO’s high-purity reagent.

• LC–MS/MS Dissects GS-441524 Prodrug Conversion and Pharmacok

  2026-06-23

  This study establishes a novel LC–MS/MS method to map the in vitro and in vivo conversion pathways of a next-generation GS-441524 prodrug (NGP-1), enhancing understanding of its pharmacokinetic profile and anti-SARS-CoV-2 potential. The findings provide mechanistic insight into prodrug activation, highlighting both methodological advances and implications for antiviral drug development.

• PFHxS-Induced Hepatotoxicity via PPARα in Zebrafish Larvae

  2026-06-22

  This study establishes that perfluorohexanesulfonic acid (PFHxS), a widely detected short-chain PFAS, disrupts liver development and lipid homeostasis in larval zebrafish through the PPARα signaling pathway. The findings clarify the mechanistic links between environmental PFHxS exposure and hepatotoxicity, providing a paradigm for metabolic disease modeling and toxicity assessment.

• TRPV1+ Nerve Stimulation: A Neural Circuit for Systemic Infl

  2026-06-22

  Song et al. (2025) reveal that targeted stimulation of TRPV1+ peripheral somatosensory nerves at the nape suppresses systemic inflammation by activating a somato-autonomic reflex. This neural-immune mechanism advances our understanding of how peripheral sensory pathways can modulate immune responses, opening new avenues for therapeutic intervention in inflammatory diseases.

• (-)-JQ1: The Benchmark JQ1 Stereoisomer for BET Inhibitor Co

  2026-06-21

  (-)-JQ1 is the gold-standard inactive JQ1 stereoisomer, empowering researchers to rigorously validate BET bromodomain inhibition in epigenetics and cancer biology workflows. By eliminating confounding off-target effects, (-)-JQ1 ensures the specificity and reproducibility of transcriptional modulation studies.

• Ibotenic Acid: NMDA Receptor Agonist for Advanced Neurodegen

  2026-06-20

  Ibotenic acid stands out as a precision NMDA receptor agonist, empowering researchers to model neurodegenerative disease and dissect brain-spinal circuits with high reproducibility. This article delivers actionable workflows, protocol enhancements, and troubleshooting insights to maximize the impact of APExBIO’s high-purity ibotenic acid in neuroscience research.

• FH1 Small Molecule: Elevating iPS-Derived Hepatocyte Maturit

  2026-06-19

  This thought-leadership article explores the mechanistic insights and translational strategy behind FH1 (Catalog No. B3700), a small molecule compound that transforms the functional landscape of iPS cell-derived hepatocytes. It combines evidence-based protocol guidance, competitive differentiation, and vision for integrating optogenetic gene therapies to inform researchers driving the future of liver cell models and regenerative applications.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page